A condition characterized by weakness, fatigue, discomfort, effort for anything and vague anxiety, without any laboratory findings or Pathological causes has been termed in the Literature Chronic Fatigue Syndrome (C.F.S.).
Literature also states that, until now, the exact cause that leads to this disorder has not been identified. However, millions of people experience the Chronic Fatigue Syndrome (C.F.S.), but nobody can explain exactly why.
An invisible Disease or condition, which also functions as an anteroom for Chronic Diseases, such as Diabetes Mellitus, Obesity, Overweight, Arterial Hypertension, and Heart Diseases. Given that the human body is led to Chronic Fatigue Syndrome through an evolutionary process, the mechanisms of which underlie and still exist after years while symptoms are apparent, it is difficult to detect it. It is a condition in which we are crawling slowly and steadily, without any significant warning, so that to be able to manage it.
According to the World Health Organization, 88% of the population suffers from Chronic Diseases.
How tired do I feel? – Chronic Fatigue
To be able to identify, diagnose, and treat Chronic condition, such as Chronic Fatigue Syndrome, a main prerequisite is to be able to “see” at the cellular level. In recent years, exams are performed mainly in the U.S.A. and Great Britain, which “photograph” the cell and give us all information we need concerning its proper function.
The causes of Chronic Diseases at cellular level, such as Chronic Fatigue Syndrome, which cannot be detected through typical exams, fall within two categories. On one hand, the deficiency of vital nutrients, and on the other on chemicals and radiation, accumulated mainly in the adipose tissue, resulting in a deviation from the basic biochemical cycle of the cell.
The names that have been given from time to time to Chronic Fatigue Syndrome (C.F.S.) are: Addison’s disease, Addison’s hypoadrenia, Subclinical hypoadrenia, Neurasthenia, Adrenal neurasthenia, Adrenal apathy.
Adrenal fatigue is the prevailing name today. In 1969, Dr. John Tinterra, a Physician specialized in low functioning of Adrenal glands, stated that 16% of people, this condition could be fatal. When Biochemical stress within an organism is increased, Adrenal glands have the role to restore balance, through the production of regulatory hormones, supporting homeostasis. If an organism functions continuously under stressful conditions and with deficiencies in nutrients, Adrenal glands show “Chronic fatigue”. These are the reasons why, until recently, this disease was not easily identifiable.
A patient saying “I feel so tired – Chronic Fatigue”, suffers from the Chronic Fatigue Syndrome.
A person may live normally due to the slow progress of the disease, thinking s/he is healthy.
However, Adrenal glands experience Chronic Fatigue, without any apparent signs of physical disease.
How tired do I feel? – Chronic Fatigue: Treatment

Chronic Fatigue Syndrome
People that may suffer from Adrenal Fatigue (Chronic Fatigue Syndrome), may present the following symptoms:
Fatigue with no apparent reason. Inability to wake up in the morning, irrespectively of hours of sleep. Intense emotional swings Unspecified anxiety. More weight that cannot be lost. Inability to face daily life. Inability to feel happy and satisfied. Reduced sexual desire (libido). Frequent and intense desire for savory or sweet snacks.
It is advisable to undergo Bio 4h type exams.
Exams at the cellular level through a simple blood sample collection, which is then sent abroad.
The results of the exams determine the Treatment Regimen for the patient, with a mean duration of three to twelve months.
In cases that there are no other Pathological conditions, the patient that thought s/he was healthy, returns to normal biochemical levels. Chronic Fatigue Syndrome and tiredness disappear, the levels of energy are high again, and s/he can face everyday life adequately.
Therapeutic Protocols for Chronic Fatigue Syndrome include Molecular nutrition, Biomimetic Hormones administration and Restoration of any deficiency, at cellular level, helping Adrenal glands to restore normal functioning.
Also read:
Biochemical, Molecular and Genetic Approach Exams
References:
- Fauci ASea. Harrison’s Principles ofIntemal Medicine. 14th ed. New York:McGraw-Hill, ρ.1965-1976,1985-1986,2003-2011,2079-2087,2035-2056,
- Hanower HR. Practical Organotherapy. Third ed. Glendale, Califomia: The Hanower Laboratory, ρ. 112–120, 1922.
- Downey DS. Balancing body chemistry with nutrition seminars; Cannonburg, ΜΙ (3rd Edition): 158, 2000.
- Hanower HR. Practical Organotherapy. Third ed. Glendale, Califomia: The Hanower Laboratory, ρ. 112-120, 1922.
- Loeb R. Sodium Chlorid ίn Treatment of a Patient with Addison’s Disease. Proc.Soc. Exper. Βίοί. and Med. 30: 808, 1933.
- Roberts SE. Exhaustion; Causes and Treatment. Emmaus, Penna 18049: Ro.dale Books, Inc., ρ. 6, 16,72-83,1966.
- Tintera JW. The Hypoadrenia Cortical State and its Management. New York State Journal ofMedicine 55 (13): 1-14, 1955.
- Tintera JW. Endocrine aspects of schizophrenia: hypoglycemia of hypoadrenocorticism. J Schizophr 1 (5): 150-181,1967.
- Tintera JW. Stabilizing Homostasis ίn the recovered alcoholic through endocrine therapy: evaluation ofthe hypoglycemic factor. J Am Geriatr Soc 14 (7), 1966.
- Tintera J. Endocrine aspects of opthalmologic and otolaryngologic allergy.
- Presented before the 27th anniversary program of the American Society of Ophthalmologic and Otolaryngologic Allergy. Chicago, IL, 1969.
- Tintera J. Hypoadrenocorticism: Endocrinologic approach to the etiology and treatment of functional hypoglycemia; non-surgical treatment of hypoglycemia states including those of alcoholism and drug addiction. The Hypoglycemia
- Foundation Inc. Scarsdale New York.: 15 pages, 1976.
- Tintera J. The Endocrine Approach to the Etiology and Effective Control of Functional Hypoglycemia. Scarsdale, ΝΥ: The Hypoglycemia Foundation, Inc.,
- Anbalagan Κ, Sadique, J. Withania somnifera (Ashwagandha), a rejuvenating herbal drug which controls alpha-2-macroglobulin synthesis during inflammation. Ιυι. J. Crude Drug Res. 23 (4): 177-183,1985.
- Baron J, Nabano, J., Slater, J., et al. Metabolic studies, aldosterone secretion rate and plasma renin after carbonoxolone sodium as biogastrone. Br. Med. J. 2: 793-795, 1969.
- Bauer U. 5-month double-blind randomized clinical trial of ginkgo biloba extract cersus placebo ίη two parallel groups ίη patients suffering from peripheral arterial insufficiency. Aezneim Forsch 34: 716-721, 1984.
- Brekhman Ι, Dardymov, IV. Pharmacological investigation of glycosides from ginseng and Eleutherococcus. Lloydia 32: 46-51, 1969.
- Brekhman Ι, Kinillow, ΟΙ Effect of Eleutherococcus οα alarm-phase of stress. Life Sci 8 (3): 113-121, 1969.
- Buittacharya S, Goel, Raj κ., Kaur, Ravinder, and Ghosal, Shibnath. AntΓ-Stress Activity of Sitoindosides νπ and ΥΙΠ, New Acysterylglucosides from Withania Somnifera. Phytotherapy Research. 1 (1): 32-37, 1982.
- Chen Μ, Shimada, F., Kato, Η, et. al. Effect of clycyerhigin ου the pharmacokinetics f prednisolone following low dosage of prednisolone hemisuccinate. Endocrinol. Japan 37: 331-341,1990.
- Cobum S, Mahuren JD, Schaltenbrand WE, Wostmann BS, Madsen D. Effects of vitamin Β-6 deficiency and 4′ – deoxypyridoxine οιι pyridoxal phosphate concentrations, pyridoxine kinase and other aspects of metabolism ίη the rat. J Nutr 111 (2): 391-198,1981.
- Colloazo Jea. Experimental hypervitaminosis ofrats caused by large doses of nadiated ergosterol. Biochem Ztschr. 204: 347-353, 1929.
- DeFeudia F. Pharmacological activities and clinical applications. Elsevier; Paris, 1991.
Leave a Reply